Advertisement

Respiratory Viruses and Other Relevant Viral Infections in the Lung Transplant Recipient

  • Ali Abedi
  • Reed Hall
  • Deborah Jo LevineEmail author
Chapter

Abstract

As advances occur in surgical technique, postoperative care, and immunosuppressive therapy, the rate of mortality in the early postoperative period following lung transplantation continues to decline. With the improvements in immediate and early posttransplant mortality, infections and their sequel as well as rejection and chronic allograft dysfunction are increasingly a major cause of posttransplant mortality. This chapter will focus on infections by respiratory viruses and other viral infections relevant to lung transplantation, including data regarding the link between viral infections and allograft dysfunction.

Keywords

Lung transplant recipients (LTR) Solid organ transplant (SOT) Lower respiratory tract (LRT) Chronic lung allograft rejection (CLAD) Bronchiolitis obliterans syndrome (BOS) Restrictive chronic lung allograft dysfunction (R-CLAD) Community-acquired respiratory virus (CARV) Respiratory syncytial virus (RSV) Parainfluenza virus (PIV) Human metapneumovirus (hMPV) Influenza Rhinoviruses (RhV) Adenovirus Coronaviruses Human bocavirus (HBoV) Cytomegalovirus (CMV) Epstein-Barr virus (EBV) Human herpes virus (HHV) BK virus Parvovirus B19 

References

  1. 1.
    Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med. 2011;184(2):159–71.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection. Respirology. 2013;18(1):22–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection—myth or reality? Am J Transplant. 2003;3(3):245–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis. 2001;33(Suppl 1):S58–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Witt CA, Meyers BF, Hachem RR. Pulmonary infections following lung transplantation. Thorac Surg Clin. 2012;22(3):403–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Norgaard MA, Andersen CB, Pettersson G. Airway epithelium of transplanted lungs with and without direct bronchial artery revascularization. Eur J Cardiothorac Surg. 1999;15(1):37–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Jordan S, Mitchell JA, Quinlan GJ, Goldstraw P, Evans TW. The pathogenesis of lung injury following pulmonary resection. Eur Respir J. 2000;15(4):790–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Verleden GM, Vos R, van Raemdonck D, Vanaudenaerde B. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant. 2010;15(5):568–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Gade J, Qvortrup K, Andersen CB, Thorsen S, Svendsen UG, Olsen PS. Bronchial arterial devascularization. An experimental study in pigs. Scand Cardiovasc J. 2001;35(3):212–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis. 1996;22(2):295–302.PubMedCrossRefGoogle Scholar
  11. 11.
    Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant. 1999;18(3):220–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar SS, Ventura AK, VanderWerf B. Influenza vaccination in renal transplant recipients. JAMA. 1978;239(9):840–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Humar A, Kumar D, Mazzulli T, Razonable RR, Moussa G, Paya CV, Covington E, Alecock E, Pescovitz MD, PV16000 Study Group. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005;5(10):2555–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Bridevaux PO, Aubert JD, Soccal PM, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle S, Nicod L, Meylan P, Wagner G, Kaiser L. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69(1):32–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Sims KD, Blumberg EA. Common infections in the lung transplant recipient. Clin Chest Med. 2011;32(2):327–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Allen U, et al. Discipline of transplant infectious diseases (ID). Foreword. Am J Transplant. 2009;9(Suppl 4):S1–2.PubMedGoogle Scholar
  17. 17.
    Smyth RL, Higenbottam TW, Scott JP, Wreghitt TG, Stewart S, Clelland CA, McGoldrick JP, Wallwork J. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49(4):735–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009;9(Suppl 4):S7–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Humar A, Michaels M, AST ID, Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–74.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11(5):1071–8.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24(4):333–43.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Krunic N, Yager TD, Himsworth D, Merante F, Yaghoubian S, Janeczko R. xTAG RVP assay: analytical and clinical performance. J Clin Virol. 2007;40(Suppl 1):S39–46.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Mahony JB. Nucleic acid amplification-based diagnosis of respiratory virus infections. Expert Rev Anti-Infect Ther. 2010;8(11):1273–92.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis. 2009;11(4):298–303.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P. Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol. 2011;50(1):42–5.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015;7(3):996–1019.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(Suppl 4):S284–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Wright B, Gross JJ, Kilburn FL, Smith AC. State of the art: research in nursing education administration. J Nurs Educ. 1992;31(9):423–4.PubMedGoogle Scholar
  30. 30.
    Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21(2):271–81.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993;12(5):713–6.PubMedGoogle Scholar
  32. 32.
    Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H, Yousem SA, Hardesty RL, Griffith BP, Duquesnoy RJ, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51(2):433–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113(4):944–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116(4):617–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119(4):1277–80.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Vilchez RA, McCurry K, Dauber J, Lacono A, Griffith B, Fung J, Kusne S. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2(3):287–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):559–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Massad MG, Ramirez AM. Influenza pneumonia in thoracic organ transplant recipients : what can we do to avoid it? Chest. 2001;119(4):997–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Faul JL, Akindipe OA, Berry GJ, Theodore J. Influenza pneumonia in a paediatric lung transplant recipient. Transpl Int. 2000;13(1):79–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Holt ND, Gould FK, Taylor CE, Harwood JF, Freeman R, Healy MD, Corris PA, Dark JH. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16(4):416–9.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Vilchez RA, McCurry K, Dauber J, Iacono A, Keenan R, Zeevi A, Griffith B, Kusne S. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33(12):2004–8.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A, Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95.PubMedCrossRefGoogle Scholar
  43. 43.
    Vilchez R, McCurry K, Dauber J, Iacono A, Keenan R, Griffith B, Kusne S. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation. 2002;73(7):1075–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation. 2002;74(2):149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Skoner DP, Gentile DA, Patel A, Doyle WJ. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis. 1999;180(1):10–4.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Arnold R, Humbert B, Werchau H, Gallati H, König W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology. 1994;82(1):126–33.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Subauste MC, Jacoby DB, Richards SM, Proud D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest. 1995;96(1):549–57.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Matsukura S, Kokubu F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy Clin Immunol. 1996;98(6 Pt 1):1080–7.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol. 1997;71(1):398–404.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 1996;273(5272):228–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Weigt SS, Derhovanessian A, Liao E, Hu S, Gregson AL, Kubak BM, Saggar R, Saggar R, Plachevskiy V, Fishbein MC, Lynch JP III, Ardehali A, Ross DJ, Wang HJ, Elashoff RM, Belperio JA. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant. 2012;12(2):477–84.PubMedCrossRefGoogle Scholar
  53. 53.
    Kohlmeier JE, Cookenham T, Miller SC, Roberts AD, Christensen JP, Thomsen AR, Woodland DL. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol. 2009;183(7):4378–84.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol. 2008;38(8):2168–79.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Belperio JA, Keane MP, Burdick MD, Lynch JP III, Xue YY, Li K, Ross DJ, Strieter RM. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol. 2002;169(2):1037–49.PubMedCrossRefGoogle Scholar
  56. 56.
    Belperio JA, Keane MP, Burdick MD, Lynch JP III, Zisman DA, Xue YY, Li K, Ardehali A, Ross DJ, Strieter RM. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol. 2003;171(9):4844–52.PubMedCrossRefGoogle Scholar
  57. 57.
    Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant. 2004;4(8):1219–26.PubMedCrossRefGoogle Scholar
  58. 58.
    Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation. 1995;59(3):313–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Humar A, Snydman D, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78–86.PubMedCrossRefGoogle Scholar
  60. 60.
    SivaSai KS, Smith MA, Poindexter NJ, Sundaresan SR, Trulock EP, Lynch JP, Cooper JD, Patterson GA, Mohanakumar T. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation. 1999;67(8):1094–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Lemstrom K Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation. 1995;92(9):2594–604.PubMedCrossRefGoogle Scholar
  62. 62.
    Community-Acquired Respiratory Viruses. Am J Transplant. 2004;4(s10):105–9.Google Scholar
  63. 63.
    Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med. 1985;78(6B):32–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5(8):2031–6.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med. 1997;102(3A):48–52; discussion 53–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther. 2007;12(4 Pt B):627–38.PubMedGoogle Scholar
  67. 67.
    Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg. 2004;16(4):342–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009;6(1):94–100.PubMedCrossRefGoogle Scholar
  69. 69.
    Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010;31(2):243–54.PubMedCrossRefGoogle Scholar
  70. 70.
    Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis. 2001;3(3):138–48.PubMedCrossRefGoogle Scholar
  71. 71.
    Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77–81.PubMedCrossRefGoogle Scholar
  72. 72.
    Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14(3):479–85.PubMedGoogle Scholar
  73. 73.
    Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102(3A):31–6; discussion 42–3.PubMedCrossRefGoogle Scholar
  74. 74.
    McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22(7):745–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, Sloots T, Nissen M. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):876–81.PubMedCrossRefGoogle Scholar
  76. 76.
    Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002;40(3):817–20.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398–401.PubMedCrossRefGoogle Scholar
  78. 78.
    Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol. 2004;31(3):358–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34–41.PubMedCrossRefGoogle Scholar
  80. 80.
    Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology. 2002;297(1):1–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Crowe JE Jr, Williams JV. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev. 2003;4(2):112–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Manuel O, Estabrook M, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):212–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12):2114–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46(4):558–66.PubMedCrossRefGoogle Scholar
  85. 85.
    Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28(1):67–71.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839–44.PubMedCrossRefGoogle Scholar
  87. 87.
    Burrows FS, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958–62.PubMedCrossRefGoogle Scholar
  88. 88.
    Flynn JD, Akers WS, Jones M, Stevkovic N, Waid T, Mullett T, Jahania S. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004;24(7):932–8.PubMedCrossRefGoogle Scholar
  89. 89.
    ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2010 Feb 5. Identifier NCT01065935, Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV); 2012 May; [3 page]. https://clinicaltrials.gov/ct2/show/NCT01065935?term=aln-rsv01&rank=2.
  90. 90.
    Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant. 2003;3(2):116–20.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12(1):38–44.PubMedCrossRefGoogle Scholar
  92. 92.
    Drozd DR, Limaye AP, Moss RB, Sanders RL, Hansen C, Edelman JD, Raghu G, Boeckh M, Rakita RM. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis. 2013;15(1):E28–32.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2012 July. Identifier NCT01644877,A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05); 2012 July; [3 page]. https://clinicaltrials.gov/ct2/show/NCT01644877?term=das181&rank=5.
  94. 94.
    Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, Fredricks DN, Corey L. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144(5):344–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Kamboj M, Gerbin M, Huang CK, Brennan C, Stiles J, Balashov S, Park S, Kiehn TE, Perlin DS, Pamer EG, Sepkowitz KA. Clinical characterization of human metapneumovirus infection among patients with cancer. J Infect. 2008;57(6):464–71.PubMedCrossRefGoogle Scholar
  96. 96.
    Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208–14.PubMedCrossRefGoogle Scholar
  97. 97.
    Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28(2):222–42.PubMedCrossRefGoogle Scholar
  98. 98.
    Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK, Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003–32.PubMedCrossRefGoogle Scholar
  99. 99.
    Kuo JH, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol. 2004;56(1):27–33.PubMedCrossRefGoogle Scholar
  100. 100.
    Hohlfeld J, Niedermeyer J, Hamm H, Schäfers HJ, Wagner TO, Fabel H. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 1996;15(9):888–94.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Armstrong C. ACIP releases recommendations for influenza vaccination, 2015-2016. Am Fam Physician. 2015;92(8):732–40.Google Scholar
  102. 102.
    Relenza® (zanamivir) [package insert]. Research Park, NC: GlaxoSmithKline; 2013.Google Scholar
  103. 103.
    Tamiflu® (oseltamivir) [package insert]. Foster City, CA: Roche; 2008.Google Scholar
  104. 104.
    Rapivab® (peramivir) [package insert]. Durham, NC: BioCryst Pharmaceuticals; 2014.Google Scholar
  105. 105.
    Centers for Disease Control and Prevention, N.C.f.I.a.R.D.N. Influenza antiviral medications: summary for clinicians. 2016 5/26/2016 6/27/2016.Google Scholar
  106. 106.
    Kaiser L, Aubert JD, Pache JC, Deffernez C, Rochat T, Garbino J, Wunderli W, Meylan P, Yerly S, Perrin L, Letovanec I, Nicod L, Tapparel C, Soccal PM. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174(12):1392–9.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Martino R, Porras RP, Rabella N, Williams JV, Rámila E, Margall N, Labeaga R, Crowe JE Jr, Coll P, Sierra J. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781–96.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    van Kraaij MG, van Elden LJ, van Loon AM, Hendriksen KA, Laterveer L, Dekker AW, Nijhuis M. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis. 2005;40(5):662–9.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32(11):1085–8.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis. 2003;36(9):1139–43.PubMedCrossRefGoogle Scholar
  111. 111.
    Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 2003;32(1):73–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey E. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis. 1999;29(3):528–32.PubMedCrossRefGoogle Scholar
  113. 113.
    Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):170–4.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol. 1995;26(10):1073–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol. 2003;13(3):155–71.PubMedCrossRefGoogle Scholar
  116. 116.
    Howard DS, Phillips GL II, Reece DE, Munn RK, Henslee-Downey J, Pittard M, Barker M, Pomeroy C. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29(6):1494–501.PubMedCrossRefGoogle Scholar
  117. 117.
    Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med. 1997;102(3A):71–4.PubMedCrossRefGoogle Scholar
  118. 118.
    Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43(3):331–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Simsir A, Greenebaum E, Nuovo G, Schulman LL. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation. 1998;65(4):592–4.PubMedCrossRefGoogle Scholar
  120. 120.
    Florescu DF, Hoffman JA, AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):206–11.PubMedCrossRefGoogle Scholar
  121. 121.
    Vistide® (cidofovir) [package insert]. Foster City, CA: Gilead Sciences; 2010.Google Scholar
  122. 122.
    Heugel J, Martin ET, Kuypers J, Englund JA. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J. 2007;26(8):753–5.PubMedCrossRefGoogle Scholar
  123. 123.
    Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F, Cariou A, Freymuth F, Lebon P. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003;37(7):929–32.PubMedCrossRefGoogle Scholar
  124. 124.
    Campanini G, Rovida F, Meloni F, Cascina A, Ciccocioppo R, Piralla A, Baldanti F. Persistent human cosavirus infection in lung transplant recipient, Italy. Emerg Infect Dis. 2013;19(10):1667–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Bastien N, et al. Human Bocavirus infection, Canada. Emerg Infect Dis. 2006;12(5):848–50.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Schenk T, Strahm B, Kontny U, Hufnagel M, Neumann-Haefelin D, Falcone V. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis. 2007;13(9):1425–7.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Miyakis S, van Hal SJ, Barratt J, Stark D, Marriott D, Harkness J. Absence of human Bocavirus in bronchoalveolar lavage fluid of lung transplant patients. J Clin Virol. 2009;44(2):179–80.PubMedCrossRefGoogle Scholar
  128. 128.
    Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181(12):1391–6.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Patel N, Snyder LD, Finlen-Copeland A, Palmer SM. Is prevention the best treatment? CMV after lung transplantation. Am J Transplant. 2012;12(3):539–44.PubMedCrossRefGoogle Scholar
  130. 130.
    Mitsani D, Nguyen MH, Girnita DM, Spichty K, Kwak EJ, Silveira FP, Toyoda Y, Pilewski JM, Crespo M, Bhama JK, Abdel-Massih R, Zaldonis D, Zeevi A, Clancy CJ. A polymorphism linked to elevated levels of interferon-gamma is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant. 2011;30(5):523–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Duncan SR, Paradis IL, Yousem SA, Similo SL, Grgurich WF, Williams PA, Dauber JH, Griffith BP. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146(6):1419–25.PubMedCrossRefGoogle Scholar
  132. 132.
    Torre-Cisneros J. Toward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the “individual pathogenic balance”. Clin Infect Dis. 2009;49(8):1167–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90(6):672–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195–200.PubMedCrossRefGoogle Scholar
  135. 135.
    Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009;9(5):1214–22.PubMedCrossRefGoogle Scholar
  136. 136.
    Razonable RR, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106.PubMedCrossRefGoogle Scholar
  137. 137.
    Clark NM, Lynch JP III, Sayah D, Belperio JA, Fishbein MC, Weigt SS. DNA viral infections complicating lung transplantation. Semin Respir Crit Care Med. 2013;34(3):380–404.PubMedCrossRefGoogle Scholar
  138. 138.
    Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A, VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.PubMedCrossRefGoogle Scholar
  139. 139.
    Cytovene® (ganciclovir) [package insert]. San Francisco, CA: Genentech; 2010.Google Scholar
  140. 140.
    Valcyte® (valganciclovir) [package insert]. San Francisco, CA: Genentech; 2015.Google Scholar
  141. 141.
    Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC, HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96–138.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45(3):260–71.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Carraro E, Perosa AH, Siqueira I, Pasternak J, Martino MD. Rotavirus infection in children and adult patients attending in a tertiary Hospital of Sao Paulo, Brazil. Braz J Infect Dis. 2008;12(1):44–6.Google Scholar
  145. 145.
    Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis. 2013;56(7):1018–29.PubMedCrossRefGoogle Scholar
  146. 146.
    Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, Waldman WJ, Braun W, Mawhorter SD, Fatica R, Krishnamurthi V, Young JB, Shrestha R, Stephany B, Lurain N, Yen-Lieberman B. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.PubMedCrossRefGoogle Scholar
  147. 147.
    Snydman DR. Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. Transplantation. 2010;90(4):362–3.PubMedCrossRefGoogle Scholar
  148. 148.
    ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2012 Jun 1. Identifier NCT01611974, Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients; 2012 July; [3 page]. https://clinicaltrials.gov/ct2/show/study/NCT01611974?term=maribavir&rank=2.
  149. 149.
    ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2015 May 7. Identifier NCT02439957, SURPASS: a randomized, double-blind, multicenter study of the efficacy, safety, and tolerability of brincidofovir versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV seropositive kidney transplant recipients (BCV CMV vGCV) (BCV CMV vGCV) ; 2015 September; [3 page]. https://clinicaltrials.gov/ct2/show/record/NCT02439957?term=cmx001&rank=14.
  150. 150.
    Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29–44.PubMedCrossRefGoogle Scholar
  151. 151.
    Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008;27(1):11–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003;124(4):1242–9.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97(5):1165–71.PubMedCrossRefGoogle Scholar
  154. 154.
    Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54; quiz 54.PubMedCrossRefGoogle Scholar
  155. 155.
    Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ. Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors. J Heart Lung Transplant. 2015;34(11):1406–14.PubMedCrossRefGoogle Scholar
  156. 156.
    Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):138–46.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Wilck MB, Zuckerman RA, AST Infectious Diseases Community of Practice. Herpes simplex virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):121–7.PubMedCrossRefGoogle Scholar
  158. 158.
    Zovirax® (acyclovir sodium) for Injection [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2003.Google Scholar
  159. 159.
    Zovirax® (acyclovir) [package insert]. Research Tringle Park, NC: Glaxo Smith Kline; 2005.Google Scholar
  160. 160.
    Valtrex® (vlacyclovir) [package insert]. Research Tringle Park, NC: Glaxo Smith Kline; 2008.Google Scholar
  161. 161.
    Famvir® (famciclovir) [package insert]. East Hanover, NJ: Novartis; 2011.Google Scholar
  162. 162.
    Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant. 2007;26(1):41–7.PubMedCrossRefGoogle Scholar
  163. 163.
    Sathy SJ, Martinu T, Youens K, Lawrence CM, Howell DN, Palmer SM, Steele MP. Symptomatic pulmonary allograft Kaposi’s sarcoma in two lung transplant recipients. Am J Transplant. 2008;8(9):1951–6.PubMedCrossRefGoogle Scholar
  164. 164.
    Sleiman C, Mal H, Roué C, Groussard O, Baldeyrou P, Olivier P, Fournier M, Pariente R. Bronchial Kaposi’s sarcoma after single lung transplantation. Eur Respir J. 1997;10(5):1181–3.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Kantor R, Mayan H, Shalmon B, Reichert N, Farfel Z. Kaposi’s sarcoma after lung transplantation in a Sephardic Jewish woman. Dermatology. 2000;200(1):49–50.PubMedCrossRefGoogle Scholar
  166. 166.
    Tereza Martinu DH, Reidy M, Palmer S. Disseminated Kaposi sarcoma in a lung transplant recipient with pulmonary, pleural, and cutaneous involvement. Chest conference 2006; 2006.Google Scholar
  167. 167.
    Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 1997;99(9):2082–6.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS. 1996;10(10):1101–5.PubMedPubMedCentralGoogle Scholar
  169. 169.
    Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, Ho M, Saah AJ. Use of antiherpes drugs and the risk of Kaposi’s sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 1996;173(6):1477–80.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Thomas LD, Vilchez RA, White ZS, Zanwar P, Milstone AP, Butel JS, Dummer S. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis. 2007;195(3):442–9.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Doucette KE, Pang XL, Jackson K, Burton I, Carbonneau M, Cockfield S, Preiksaitis JK. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation. 2008;85(12):1733–6.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant. 2005;5(10):2582–5.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation. 2009;88(3):360–6.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review. Transplant Rev (Orlando). 2015;29(3):175–80.CrossRefGoogle Scholar
  175. 175.
    Kariyawasam HH, Gyi K, Hodson M, Cohen B. Anaemia in lung transplant patient caused by parvovirus B19. Thorax. 2000;55(7):619–20.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol. 2002;40(3):933–6.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75(2):97–102.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Authors and Affiliations

  1. 1.Department of Pulmonary and Critical Care MedicineUniversity of Texas Health San AntonioSan AntonioUSA
  2. 2.PharmacyUniversity Hospital—University Health SystemSan AntonioUSA

Personalised recommendations